- Home
- RRR vs LNTH Comparison
RRR vs LNTH Comparison
Compare RRR & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | LNTH |
|---|---|---|
| Founded | 1976 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.2B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RRR | LNTH |
|---|---|---|
| Price | $56.23 | $63.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | $61.40 | ★ $74.17 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 15.51 | N/A |
| EPS | ★ 3.14 | 2.39 |
| Revenue | ★ $1,995,401,000.00 | $1,525,933,000.00 |
| Revenue This Year | $4.13 | $0.01 |
| Revenue Next Year | $3.47 | $1.24 |
| P/E Ratio | ★ $17.92 | $26.45 |
| Revenue Growth | ★ 4.69 | 1.95 |
| 52 Week Low | $35.09 | $47.25 |
| 52 Week High | $63.60 | $111.29 |
Technical Indicators
Market Signals| Indicator | RRR | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 71.16 |
| Support Level | $58.02 | $57.44 |
| Resistance Level | $59.93 | $59.30 |
| Average True Range (ATR) | 1.76 | 2.14 |
| MACD | 0.10 | 0.82 |
| Stochastic Oscillator | 46.70 | 91.35 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.